AI Article Synopsis
- Solid organ transplantation has significantly improved over the years, mainly due to advancements in immunosuppression strategies.
- Current trends are moving away from traditional steroids, focusing on steroid-free regimens, with new agents aiding in induction, maintenance, and acute rejection treatment.
- Innovative therapies like MTOR inhibitors and rituximab are reducing side effects and donor-specific antibodies, ultimately lowering acute rejection rates in transplant patients.
Article Abstract
Solid organ transplantation and survival has improved tremendously in the last few decades, much of the success has been attributed to the advancements in immunosuppression. While steroids are being replaced and much of the immunosuppressive strategies focus on steroid free regimens, novel agents have introduced in the induction, maintenance, and treatment of acute rejection phase. MTOR inhibitors have helped with the renal sparing side effect from the calcineurin inhibitors, newer agents such as rituximab have decreased the incidence of donor-specific antibodies which led to decreased incidence of acute rejection reactions. In this chapter we discuss the newer therapies directed specifically for solid organ transplantation.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/164_2021_569 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!